Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nutri'Earth has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners across 2 distinct art units. This one-to-one ratio of examiners to art units suggests that each pending matter is being evaluated in a different specialized environment. For the practitioner, this means that the prosecution of the 2 pending office actions must be managed as two separate technical tracks.
SONG, JIANFENG is the busiest examiner for this portfolio, with 1 pending office action. Given that there are 2 pending office actions and 2 distinct examiners, each examiner is responsible for exactly one action. This distribution requires the company to manage two separate prosecution strategies simultaneously within the pharmaceutical field. The presence of 2 distinct art units further confirms that the subject matter is being reviewed by different specialized groups. Practitioners must be careful to maintain consistency across the 2 distinct examiners while addressing the specific technical requirements of each art unit. This structure indicates a diversified biotechnology portfolio where each pending action faces a unique examination path.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
| HAWKINS, AMANDA SALATA | 1 | 12.0% | +45.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18249129 | ULTRAVIOLET TREATMENT OF COLEOPTERA LARVAE OIL FOR VITAMIN D3 ENRICHMENT | HAWKINS, AMANDA SALATA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576229 | IMPROVED ENRICHMENT OF VITAMIN D3 IN TRANSFORMED COLEOPTERAN LARVAE BY A METHOD OF ULTRAVIOLET TREATMENT AND ASSOCIATED FOOD POWDER | SONG, JIANFENG | — |
| 18249129 | ULTRAVIOLET TREATMENT OF COLEOPTERA LARVAE OIL FOR VITAMIN D3 ENRICHMENT | HAWKINS, AMANDA SALATA | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576229 | IMPROVED ENRICHMENT OF VITAMIN D3 IN TRANSFORMED COLEOPTERAN LARVAE BY A METHOD OF ULTRAVIOLET TREATMENT AND ASSOCIATED FOOD POWDER | SONG, JIANFENG | 1613 | §103§112DP | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18249129 | ULTRAVIOLET TREATMENT OF COLEOPTERA LARVAE OIL FOR VITAMIN D3 ENRICHMENT | HAWKINS, AMANDA SALATA | 1793 | §103§112 | Final Rejection | — | Pending | Apr 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial